Clinical trial · Observational
Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients
NCT06281912CI-TRIAL-00074456MELCAYAunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective observational cohort study, the primary objective is investigate the activity and efficacy of anti PD-1 antibodies in children, adolescents and young adult melanoma patients, with radically resected or metastatic disease
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Melanoma | Melanoma | CURATED_BROADER | 0.78 |
| Early Melanoma | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- adolescent/childhood
- description
- patients \<20 years old with with stage III and IV melanoma diagnosis
- label
- young adult
- description
- patients \< 30 years with stage III and IV melanoma diagnosis
Primary outcomes (1)
- measure
- rate of objective response
- timeFrame
- 12 months
- description
- efficay of anti PD-1 antibodies in adolescent, childhood and young through Tumor assessment revision adult with early and advanced melanomas
Secondary outcomes (1)
- measure
- adverse event incidence
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients of either sex aged ≥ 12 years; 2. Histologically confirmed melanoma; 3. Anti PD-1 Immunotherapy (Ipilimumab plus Nivolumab); 4. Previous and subsequent treatments will be collected; 5. Clinical and follow-up data available Exclusion Criteria: 1. No immunotherapy received; 2. No melanoma; 3. Age \> 30 yrs
References
Publications (0)
Data not yet available
No reference posted for this study.